PT-141 for women is FDA-approved as Vyleesi for premenopausal HSDD, not as a nasal spray. Compare dosing, benefits, side effects, and safety.
PT-141 (bremelanotide) is a prescription drug the FDA approved in 2019 under the brand name Vyleesi for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). It is given as a subcutaneous injection, not as a nasal spray, and it is not approved for postmenopausal women. Any PT-141 nasal spray sold online is an unapproved research chemical with no established dose.
How PT-141 Works in Women
Bremelanotide activates melanocortin receptors in the brain, especially the MC4 receptor, which are involved in the pathways that regulate sexual desire. It works centrally rather than on blood flow, so it is not a female version of Viagra.
That distinction matters. PDE5 inhibitors address vascular problems, while bremelanotide targets desire and the distress that comes with low desire. A woman can have normal arousal physiology and still respond to PT-141, or the opposite can be true.
Does PT-141 Work for Women? Evidence, Benefits, and Limits
If you are asking does pt-141 work for women, the honest answer from the Phase 3 RECONNECT trials is: modestly, and only for some. Roughly 1,200 premenopausal women with HSDD were studied, and those on bremelanotide reported small gains in desire and small reductions in distress compared with placebo.
The main pt-141 for women benefits reported in those trials were slightly higher desire scores and less bother about low desire. The average effect worked out to about one additional satisfying sexual event every two months, which is meaningful for some women and disappointing for others.
PT-141 does not fix relationship conflict, pain with penetration, or genitourinary symptoms of menopause. Sexual medicine studies also produce strong placebo responses, so part of the improvement reported in trials likely reflects expectation rather than pharmacology alone.
Women whose HSDD is acquired (it began after a period of normal desire) and generalized (present in most situations) tend to be the best candidates for evaluation.
PT-141 Dosage for Women: Labeled Use vs. Off-Label Practice
The labeled pt-141 dosage for women is 1.75 mg injected under the skin of the abdomen or thigh, at least 45 minutes before anticipated sexual activity. Do not use more than one dose in 24 hours, and do not exceed eight doses in a single month.
The dose is fixed, with no titration up or down. Going above eight doses per month raises the risk of focal hyperpigmentation, which is darkening of the skin, gums, or breasts that may persist after the drug is stopped. That risk is one of the reasons the monthly ceiling exists.
| Option | Form | FDA status | Typical use |
|---|---|---|---|
| Bremelanotide (Vyleesi) | Subcutaneous injection | Approved for premenopausal HSDD | 1.75 mg as needed, max 8 doses per month |
| Bremelanotide nasal spray | Nasal spray | Not approved for any use | No established dose; sold as a research chemical |
| Flibanserin (Addyi) | Oral tablet | Approved for premenopausal HSDD | Taken nightly at bedtime |
PT-141 Nasal Spray for Women: What You Are Actually Buying
Bremelanotide was first studied as a nasal spray, but the developer shifted to injection after nasal delivery produced inconsistent absorption and sharper blood pressure increases. As a result, there is no FDA-approved pt-141 nasal spray dosage for women.
Products marketed as PT-141 nasal spray come from peptide and research chemical vendors. They are not reviewed for purity, sterility, or actual drug content, and using them for personal treatment is not legal in the United States.
If a website advertises a specific nasal spray dose, that number has not been reviewed by the FDA. Laboratory research use is a separate category from medical treatment, and the two should never be blended in marketing claims.
PT-141 for Women Side Effects and Safety Warnings
Among the pt-141 for women side effects, nausea is the most common, reported by roughly 40% of participants in the Phase 3 trials. Flushing, headache, injection site reactions, and vomiting also occur, and they typically appear within the first hour after dosing.
Bremelanotide temporarily raises blood pressure and can slightly slow heart rate. It is contraindicated in women with uncontrolled high blood pressure or known cardiovascular disease, and it should not be combined with other blood-pressure-raising drugs without medical guidance.
| Side effect | Approximate rate in trials | Notes |
|---|---|---|
| Nausea | About 40% | Most common reason women stop treatment |
| Flushing | About 20% | Usually brief, affecting face and neck |
| Headache | About 12% | Often mild |
| Injection site reaction | About 13% | Bruising, pain, or itching |
| Focal hyperpigmentation | Less common | Associated with frequent daily dosing |
Women who are pregnant, breastfeeding, or managing heart disease should not use bremelanotide without a clinician's clearance. Severe or persistent nausea, chest pain, or new skin darkening should be reported to a doctor promptly.
PT-141 and Menopause: What Postmenopausal Women Should Know
The FDA label covers premenopausal women only. Postmenopausal sexual desire concerns are common and are often tied to falling estrogen, but bremelanotide was not approved for that group, and published data in postmenopausal women remain limited.
Postmenopausal women exploring treatment usually start with a discussion of vaginal estrogen, pelvic floor physical therapy, off-label testosterone, or sex therapy, ideally with a clinician experienced in menopause care. Some prescribers do offer PT-141 off-label after menopause, but that decision should weigh cardiovascular risk, cost, and realistic expectations.
PT-141 is a legitimate prescription option for a narrow group of premenopausal women, and it is not a proven or approved treatment for everyone else. Anyone considering it, injected or as a nasal spray, should talk with a healthcare professional about heart health, current medications, and what a realistic result would look like.
Frequently Asked Questions
Can women use PT-141 nasal spray?
No nasal spray form of PT-141 is FDA-approved. The approved product, Vyleesi, is a subcutaneous injection for premenopausal women with hypoactive sexual desire disorder. Nasal sprays sold online are unapproved research chemicals with unknown purity and no established dose.
How long does PT-141 take to work in women?
The labeled instructions say to inject bremelanotide at least 45 minutes before anticipated sexual activity, and many women notice effects within one to two hours. Side effects such as nausea and flushing usually appear in that same window and fade over a few hours. Only one dose is allowed in a 24-hour period.
Is PT-141 safe for postmenopausal women?
PT-141 is not FDA-approved for postmenopausal women, and clinical evidence in that group is limited. Because the drug temporarily raises blood pressure, postmenopausal women with cardiovascular risk factors should be evaluated by a clinician before considering off-label use. Other options, including vaginal estrogen and pelvic floor therapy, may be discussed first.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.